Literature DB >> 30380036

Pneumatic dilation versus laparoscopic Heller's myotomy in the treatment of achalasia: systematic review and meta-analysis based on randomized controlled trials.

P Bonifácio1, D T H de Moura1, W M Bernardo1, E T H de Moura1, G F A Farias1, A C M Neto1, M Lordello1, N Korkischko1, R Sallum1, E G H de Moura1.   

Abstract

Achalasia is a primary esophageal motor disorder with a variety of causes. It is most common in Central and South America, where Chagas disease is endemic. In addition to the infectious etiology, achalasia can be idiopathic, autoimmune, or drug induced. It is an incurable, progressive condition that destroys the intramural nerve plexus, causing aperistalsis of the esophageal body and impaired relaxation of the lower esophageal sphincter. The literature on the treatment of achalasia comparing pneumatic dilation (PD) and laparoscopic Heller's myotomy (LHM) shows conflicting results. Therefore, a systemic review and meta-analysis are needed. A systematic review and meta-analysis of randomized controlled trials of PD and LHM, based on the preferred reporting items for systematic reviews and meta-analyses recommendations, was presented. The primary outcome was symptom remission based on the Eckardt score. Secondary outcomes were lower esophageal sphincter pressure (LESP), gastroesophageal reflux (GER), and perforation. A total of four studies were included in this analysis. The total number of patients was 404. Posttreatment symptom remission rates did not differ significantly between LHM and PD at 2 years (RD = 0.03, 95% CI [-0.05, 0.12], P = 0.62), or 5 years (RD = 0.13, 95% CI [-0.12, 0.39], P = 0.32). The posttreatment perforation rate was lower for LHM (RD = 0.04, 95% CI [-0.08, -0.01], P = 0.03). There was no significant difference in terms of LESP or GER. For the treatment of esophageal achalasia, LHM and PD were found to be similar in terms of their long-term efficacy, as well as in terms of the posttreatment GER rates. However, the perforation rate appears to be lower when LHM is employed.

Entities:  

Mesh:

Year:  2019        PMID: 30380036     DOI: 10.1093/dote/doy105

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  Considering the first randomized trial of peroral endoscopic myotomy versus surgical myotomy for achalasia.

Authors:  Cem Şimşek
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

2.  Reflux symptoms and oesophageal acidification in treated achalasia patients are often not reflux related.

Authors:  Fraukje A Ponds; Jacobus M Oors; André J P M Smout; Albert J Bredenoord
Journal:  Gut       Date:  2020-05-21       Impact factor: 23.059

3.  Efficacy and safety of Chinese medicine combined with balloon dilatation vs. balloon dilatation alone for achalasia patients: a systematic review and meta-analysis.

Authors:  Junqian Chen; Xiaoxun Huang; Yingting Li; Haomeng Wu; Shumin Qin; Huan Zheng; Jianhua Li; Haiyan Zhang; Lijuan Hu; Shaogang Huang
Journal:  Ann Transl Med       Date:  2022-03

4.  Peroral endoscopic myotomy vs laparoscopic myotomy and partial fundoplication for esophageal achalasia: A single-center randomized controlled trial.

Authors:  Eduardo Turiani Hourneaux de Moura; José Jukemura; Igor Braga Ribeiro; Galileu Ferreira Ayala Farias; Aureo Augusto de Almeida Delgado; Lara Meireles Azeredo Coutinho; Diogo Turiani Hourneaux de Moura; Rubens Antonio Aissar Sallum; Ary Nasi; Sergio A Sánchez-Luna; Paulo Sakai; Eduardo Guimarães Hourneaux de Moura
Journal:  World J Gastroenterol       Date:  2022-09-07       Impact factor: 5.374

5.  European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations.

Authors:  R A B Oude Nijhuis; G Zaninotto; S Roman; G E Boeckxstaens; P Fockens; M W Langendam; A A Plumb; Ajpm Smout; E M Targarona; A S Trukhmanov; Blam Weusten; Albert J Bredenoord
Journal:  United European Gastroenterol J       Date:  2020-02       Impact factor: 4.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.